Browse by category

Researchers from the Keck School of Medicine (University of Southern California) have found that teenagers with higher blood levels of per- and polyfluoroalkyl substances (PFAS) measured before metabolic bariatric surgery (MBS) had smaller improvements in blood sugar over five years, including fasting glucose and haemoglobin A1c (HbA1c), which measures average blood sugar levels over the past 60–90 days. The results, suggest that PFAS exposure may help explain why metabolic o

Laparoscopic vertical clip gastroplasty (LBCG) using the nonadjustable BariClip is a safe and effective bariatric procedure in the short term, with significant reductions in BMI, %TWL and %EWL observed over a six-month period, according to a retrospective observational study by researchers from Jordan. Figure 1: Schematic illustration of laparoscopic vertical clip gastroplasty using the nonadjustable BariClip system, showing the placement of the clip along the stomach to cre

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including FundoRing-OAGB modification, magnet-assisted bariatric surgery, Bariclip, ring-augmented sleeve gastrectomy and the SURMOUNT-4 Trial, and more (please note, log-in maybe required to access the full paper). Comparative endoscopic ultrasound assessment of the gastric pouch after F

Just a few months after the world’s first gastric mucosal ablation (GMA) case using MOVIVA (Erbe Elektromedizin) at the Policlinico Universitario Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA is helping to establish a new era of endoscopic bariatric treatment – offering a less invasive option as obesity rates continue to rise worldwide. Gastric mucosal a

The World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease, to address the growing global health challenge of obesity that affects more than one billion people. In 2024, obesity was associated with 3.7 million deaths worldwide and without decisive action, the number of people with obesity is projected to double by 2030. In September 2025, WHO added GLP-1 ther

Fractyl Health has announced positive 6-month results from its open-label REVEAL-1 Cohort. The REVEAL-1 Cohort is an open-label study in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. The REVEAL-1 data show that patients who underwent a single Revita procedure after discontinuing GLP-1 therapy maintained both stable body weight and glycaemic control through 6 mont